001027713 001__ 1027713
001027713 005__ 20250203103452.0
001027713 0247_ $$2doi$$a10.1055/s-0043-1766271
001027713 037__ $$aFZJ-2024-04023
001027713 1001_ $$0P:(DE-Juel1)177960$$aSchweda, V.$$b0$$ufzj
001027713 1112_ $$a61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin$$cLeipzig$$d2023-04-19 - 2023-04-22$$wGermany
001027713 245__ $$aRegional grey-matter A1 adenosine receptor expression in patients with early-stage Multiple Sclerosis: An in vivo PET study
001027713 260__ $$c2023
001027713 3367_ $$033$$2EndNote$$aConference Paper
001027713 3367_ $$2DataCite$$aOther
001027713 3367_ $$2BibTeX$$aINPROCEEDINGS
001027713 3367_ $$2DRIVER$$aconferenceObject
001027713 3367_ $$2ORCID$$aLECTURE_SPEECH
001027713 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1719375383_25156$$xAfter Call
001027713 520__ $$aZiel/Aim Various studies indicate that cerebral adenosine modulates autoimmuneand inflammatory conditions. In line, experiments in rodents as well aspost-mortem investigations in humans suggested that adenosine and the A1adenosine receptor (A1AR), which is the most abundant adenosine receptor inthe brain, plays an important role in the pathogenesis of multiple sclerosis (MS).In this study, we investigated the in vivo cerebral A1AR availability in earlystageMS patients.Methodik/Methods Cerebral A1AR availability was investigated in vivo via PETwith the A1AR-specific radiotracer F-18-CPFPX in 15 early-stage MS patientsbeing free of disease-specific medication, as well as in 14 age- and sex-matchedhealthy controls. Regional A1AR availability was determined quantitatively forgrey matter volumes of interest (VOI) by equilibrium analysis and comparedbetween patients and controls, between subgroups of patients, and betweenpairs of VOIs located on both hemispheres of the brain.Ergebnisse/Results There were no global differences in A1AR availability ingrey matter regions of MS patients in comparison to healthy controls nor withinclinical MS subtypes. However, single brain regions exhibited significant differencesin A1AR availability between both hemispheres (precentral gyrus, postcentralgyrus, cerebellum, presubgenual frontal cortex, subgenual frontalcortex, posterior part of superior temporal gyrus, anterior part of superiortemporal gyrus) in MS patients.Schlussfolgerungen/Conclusions Summarizing, this study shows that thereare no global alterations of A1AR availability in cerebral grey matter at earlystages of MS pathology. However, we observed patient-specific interhemisphericdeviations of A1AR grey matter availability that require further investigation.
001027713 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001027713 588__ $$aDataset connected to CrossRef Conference
001027713 7001_ $$0P:(DE-HGF)0$$aGraf, J.$$b1
001027713 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, D.$$b2$$ufzj
001027713 7001_ $$0P:(DE-Juel1)138474$$aMatusch, A.$$b3$$ufzj
001027713 7001_ $$0P:(DE-HGF)0$$aIngwersen, J.$$b4
001027713 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, B.$$b5$$ufzj
001027713 7001_ $$0P:(DE-HGF)0$$aAktas, O.$$b6
001027713 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b7$$ufzj
001027713 7001_ $$0P:(DE-Juel1)131691$$aKroll, T.$$b8$$ufzj
001027713 773__ $$a10.1055/s-0043-1766271
001027713 909CO $$ooai:juser.fz-juelich.de:1027713$$pVDB
001027713 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177960$$aForschungszentrum Jülich$$b0$$kFZJ
001027713 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich$$b2$$kFZJ
001027713 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)138474$$aForschungszentrum Jülich$$b3$$kFZJ
001027713 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b5$$kFZJ
001027713 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b7$$kFZJ
001027713 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich$$b8$$kFZJ
001027713 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001027713 9141_ $$y2024
001027713 920__ $$lyes
001027713 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001027713 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
001027713 980__ $$aconf
001027713 980__ $$aVDB
001027713 980__ $$aI:(DE-Juel1)INM-5-20090406
001027713 980__ $$aI:(DE-Juel1)INM-2-20090406
001027713 980__ $$aUNRESTRICTED